收藏本站
收藏 | 手机打开
二维码
手机客户端打开本文

rIL-25在急性溃疡性结肠炎中的抗炎症效应

Salum Seif Salum Mchenga  
【摘要】: Objective Inflammatory Bowel Diseases(IBD)is a collective term for the unknown etiology gastrointestinal disorders such as Crohn's disease(CD)and Ulcerative Colitis(UC) associated with chronic relapsing inflammation.Over recent decades the incidence of IBD has been rising in the world,and IBD will become increasingly common in Asia, as it has been in the last fifty years in Europe and North America.The most recent review of Chinese literature reveals that 143 511 cases of IBD(140 120 of UC and 3391 of CD)were described during the last 15 years,with an 8.5-fold increase during the last 5 years compared with the first 5 years.Although the precise etiology of IBD has not been characterized,the most recent hypothesis concerning the underlying disease mechanism states that individuals who have a genetic predisposition,when confronted with unidentified aggressors from their natural environment,develop a loss of tolerance to luminal bacterial antigens and initiate an uncontrolled inflammatory reaction targeted at the bowel wall and at distant organ systems such as the joints,skin, or biliary tract.Crohn's disease manifests itself as a chronic granulomatous inflammation of the gastrointestinal tract capable of affecting its entire length with the presence of“skip”lesions.Ulcerative colitis,on the contrary,presents as a continuous inflammatory lesion affecting the rectum and colon,lacking granulomatous characteristics.These two forms of IBD appear to show a distinct profiles of T cell mediated immunity.In patients with Crohn's disease,the patterns of cytokines expressed by mucosal lymphocytes generally tend to be consistent with a T-helper-1(Th1)response,including an early increase in the expression of interferon (IFN),IL-2,and IL-12,followed by a subsequent increase in tumor necrosis factor-(?) (TNF-(?))and IL-18.Furthermore,there also appears to be a compensatory increase in IL-10 and transforming growth factor-β1(TGF-β1)levels.In patients with ulcerative colitis,the pattern of cytokine expression differs from that seen in Crohn's disease,with an increased expression of IL-5,IL-6,IL-10,and IL-13.This Th2 response is up-regulated in the colon of UC,although the relevance of elevated Th2 cytokines to the colonic inflammation has not yet been clarified,an increased pro-inflammatory cytokine production observed seems to be related to the inflammation. IL-25/IL-17E is a fifth member of the structurally related IL-17 cytokine family. IL-25 was first discovered in human genomic sequence following analysis of human genomic DNA sequence information available in GenBankTM(accession number CNS01DTR).The human IL-25 gene has been mapped to the region 14q11.2 and spans a region of about 3595bp(according to GenBank accession number NT-026437.Two alternatively spliced mRNA transcripts of the gene encoding two distinct isoforms have been described,the IL-25 isoform 1 precursor(GenBank accession number NM-022789)and the IL-25 isoform 2(GenBank accession number NM-172314).Both mRNAs contain two exons,and isoform 2 lack in internal segment compared to isoform1,leading to a shorter N-terminus.The mRNA isoform 1 is predicted to result into a 177-amino acid protein,while the mRNA for isoform 2 is predicted to encode 161-amino acid protein.The two isoforms are identical in the last 159 carboxy terminal amino acids.A different in the physiological effect of the two isoforms has not yet been detected.IL-25 is secreted as a disulfide linked homodimer of glycoprotein incorporating cysteine residues,with a molecular weight of 34kDa.Structurally,all six family members(IL-17A to IL-17F)conserved cysteine residues that accounting for a characteristic of forming a cysteine-knots and in this respect is related to other better known cytokines such as TGF-βand platelet-derived growth factor. The receptor for IL-25 was first identified as an IL-17B receptor(IL-17BR)also called IL-17 receptor homolog 1(IL-17Rh1)and EVI27.Murine EVI27 was identified through its location at a common site of retroviral integration in BXH2 murine myeloid leukemias.Co-immunoprecipitation experiments have shown that IL-25 is the main ligand for 7BR,while IL-17B demonstrated to interact with 17BR with low affinity.Sequence comparison of the receptors for IL-17A and IL-25 reveals similar overall structure with conservation of several cysteines within the extracellular domains,and also with conserved elements within the intracellular domain,suggesting that these receptors likely engage similar signaling pathways.Indeed,IL-25 was shown to activate NF-κB and to induce the production of chemokine IL-8 in the human renal carcinoma cell line TK-10.IL-17Rh1 shows highest level expression in kidney with moderate expression in multiple other organs,whereas IL-25 mRNA was detected at very low levels in several peripheral tissues,including colon,uterus,stomach,small intestine,kidney,and lung. Native IL-25 expression has been detected from in vitro-differentiated Th2 cells and in vitro-cultured mast cells.However,when the induction of Th2 cytokines was analyzed in vitro,the major cell type in response to IL-25 appears to be a non-T/non-B cell population expressing classⅡMHC and CD 11 c molecules,a typical accessory cell phenotype.Treatment of mice with purified IL-25 resulted in the production of cytokines IL-4,IL-5,and IL-13,eosinophilia,increased serum Ig,and the development of striking histological changes in the lungs and the gastrointestinal(GI)tract.Similarly, administration of recombinant IL-25(rIL-25)to mice has been shown to evoke an inflammatory response characterized by the overproduction of Th2 cytokines,hyper production of immunoglobulin IgA and IgE,overproduction of mucus,epithelial cell hyperplasia,and eosinophilia. DSS-induced experimental colitis is widely regarded as a useful murine model of IBD,that reliable for the IBD cellular and molecular studies.The DSS model is easily induced,reproducible,and Th1 cytokine response in acute model reported to resemble that observed in human inflammatory conditions such as IBD.Several animal models for intestinal inflammation have been developed.Oral administration of DSS in drinking water of in several mammals such as mice,rats,guinea pigs and hamsters are able to induce not only an acute,but also a chronic colitis after multiple cycles of DSS. Acute colitis in mice is manifested by diarrhea,weight loss,shortening of the colon, mucosal ulceration,and inflammatory cell infiltration into the left colon.A chronic colitis can be induced in several mammals by feeding them with DSS in their drinking water in cycles of 7 days of DSS followed by 7 days of water.Chronic lesions are marked by increased plasma cells,lymphocytes,macrophages,lymphoid aggregates in the lamina propria as well as the serosa and a patchy distribution of inflammation together with fissuring ulcers.The histopathology of this model resembles to UC and would enable research into the pathogenesis of this disease.Thus,the main objective of this study is to evaluate the effect of rIL-25 on the development of inflammatory Bowel diseases. Methods 1.Establishment of UC mouse model Female,C57BL/6 mice aged 6-8 weeks,weighed between 18-22g were used in this experiments,they were randomly divided into DSS+rIL-25 treated group,DSS treated group and control group.Acute experimental colitis was induced by oral administration of DSS in drinking water ad libitum for five consecutive days.Mice in the DSS+rIL-25 treated groups and DSS treated group were administered with 2.5% (wt/vol)DSS in drinking water ad libitum while inspected for the development of clinical symptoms,macroscopic changes at autopsy and histological damage.Mice in control group were given free access to normal drinking water. 2.Treatment of mice with rIL-25 At the start of DSS exposure,mice in the DSS+rIL-25 treated groups were injected i.p.with different concentration of rIL-25 starting from 0.2,0.4 to 0.8μg in PBS respectively.Mice in control group were only injected with PBS.Mice in the DSS treated group were only injected i.p.with 0.1ml of PBS,from day 0 to day 5.Mice in the control group were not given any treatment.Mice were sacrificed on time point basis at day 3 and day 6. 3.Assessment of colitis Development and progress of acute colitis was assessed clinically, macroscopically and histologically.Assessment Clinical assessment of DSS-induced colitis were performed in all animal on a daily basis,this including,assessment of mice body weight,evaluation of stool consistency and,visible blood stool.Disease activity index were determined by combining sum of total scores divided by three.Macroscopic assessment of inflammation was performed at autopsy by measuring colon length,and assessing changes in colon gross appearance and presence of colonic blood. Histological assessment was performed on the colon tissue sections and all histological evaluation will be performed in a blinded fashion according morphological criteria grading method. 4.Survival study For survival study,10 mice from each DSS+rIL-25 treated group and the control group were continuously subjected to DSS until day 7 when they were returned to normal drinking water while assessed for their survival. 5.Cytokine assays ELISA technique will be used for measurement of transforming growth factor (TGF)-β1,IL-23,IL-25,IL-17,IL-10,IL-4,and IFN-γ.Spleen supernatants and colonic tissue homogenates samples from each mice group will be analyzed according with provided kit manufactures protocols.The spleens from each treatment group were aseptically removed,placed in 100 mm tissue culture dishes,flushed with PBS supplemented with 2%fetal calf serum(2%FCS PBS)using a 5 ml syringe,and then cells were centrifuged to a pellet at 1,500 rpm.Red blood cells were lysed from spleen samples by incubating cell suspensions for 5 min at 4℃in erythrocyte lysis buffer(170 mM Tris,160 mM NH4Cl,pH 7.4),followed by two washes in 2%FCS PBS at 1,500 rpm.The supernatants were discarded and the cells were resuspended in RPMI 1640 supplemented with 10%FCS.The cells were counted with a hemocytometer,adjusted at 2×10~6 and then cultured in RPMI 1640 at 37℃in a humidified incubator with 5% CO_2 for 48 hours.Cells were harvested centrifuged and supematants were collected for cytokines analysis.Colon tissue homogenates were prepared for cytokines analysis.the distal colons from each group were collected and homogenized with PBS homogenizing buffer containing 1%Triton X-100 supplemented with cocktail of protease inhibitors.The homogenized solutions were centrifuged at 12,000 rpm for 10 min,and the supematants were separated into aliquots and stored at -70℃. 6.RNA extraction and Reverse Transcription-Polymerase Chain Reaction(RT-PCR). Total cellular RNA was isolated from frozen distal colonic tissue by homogenization of the tissue in TRIzol and incubation at room temperature for 5 min. RNA was extracted with chloroform 0.2ml/ml of TRIzol reagent,the samples were shake vigorously,incubated at room temperature for 3 min and then centrifuged for 15 min at 10,000 rpm at 4℃.The aqueous phase was transferred to fresh tubes then precipitated with an equal volume of isopropanol and subsequently centrifuged for 15 min at 10,000 rpm at 4℃.The pellet was washed with 70%ethanol and resuspended in 50μl of DPEC water.Total RNA was determined by spectrometric analysis.RT-PCR was performed in single reaction tubes using the TaKaRa RNA PCR kit.The following primer pairs were used for the PCR:mouse IL-25,5'-GAGGCTTCTGGACTGCGGTGGTCC-3' and 5'-TTGACAG GCGAGGGTCACAGCTCC-3.The RNA reverse transcription was performed in a final volume of 10μl containing 2μl MgCl2(25 mM),1μl 10×RT buffer,3.75μl RNase free water,1μl dNTP mixture(10 mM),0.25μl RNase inhibitor (40/μl),0.5μl Avian Myeloblastosis Virus(AMV)reverse transcriptase(50U/μl),0.5μl random mers(50 pmol/μl),and 1μl positive control RNA.Reactions were incubated at 42℃for 50 min,and then heat-inactivated at 70℃for 15 min.After reverse transcription,the cDNA was aliquoted into tubes that contained specific primer pairs for the mouse IL-25.Briefly,PCR amplifications were performed by addition of 80μl of a master mix containing 10μl 5×RT buffer,28.75μl double distilled water,0.25μl TaKaRa Ex Tag HS 5U/μl,0.5μl Primer 1,0.5μl Primer 2 and 40μl of sample.RNA positive control mixture contained 10μl 5x RT buffer,28.75μl double distilled water, 0.25μl TaKaRa Ex Tag HS 5U/μl,0.5μl control F-1 Primer(20 pmol/μl),and 0.5μl control R-1 Primer(20 pmol/μl).PCR was performed in a thermocycler with an initial denaturation step of 94℃for 5 min,followed by 28 cycles of 1 min at 94℃,1 min at 55℃,and 1 min at 72℃with a final extension at 72℃for 10 min.The amplified PCR products were electrophoresed on a 1%agarose gel together with the 100-bp DNA ladder marker. 7.Western blot analysis Frozen distal colonic tissues 100 mg from each group were collected and homogenized with RIPA Lysis Buffer(100mg/ml)supplemented with aprotinin cocktail of inhibitors(0.06μg/ml)and then were incubated at 4℃for 10 min The homogenized solutions were centrifuged at 12,000 rpm at 4℃for 10 min,and the supernatants were separated and the protein concentration in the lysates was quantified with a BCA protein assay kit using bovine serum albumin as a standard.Total protein lysates 20μg per lane were loaded and electrophoresed on a 10%SDS-PAGE before were electro-transferred to Hybond polyvinylidene difluoride membranes at 70 V for 2 h. The membrane was blocked with 5%nonfat milk in Tris-buffered saline supplemented with 0.05%Tween 20(pH 7.6)for 2 h,and incubated with the goat anti-mouse IL-25 polyclonal antibody at a dilution of 1:1000 at 4℃overnight.After washing,membrane was incubated with horseradish peroxidase-conjugated anti-mouse secondary antibody at a dilution of 1:5,000 at room temperature for 2 h.After extensive washing,the blot was developed by using ECL chemiluminescent detection kit according to the manufacturer's instructions and the target protein images were obtained by Bio-Imaging System. 8.Immunohistofuorescent staining Sections(5μm)were pretreated by boiling in citrate buffer(pH 6.1)in a microwave. After cooling,non-specific binding was blocked with 5%BSA blocking reagent followed by incubation with primary antibody goat polyclonal anti-mouse IL-25 at a dilution of 1:100 in phosphate buffered saline(PBS)overnight at 4℃in a humidified chamber.As a negative control,sections were incubated with normal goat IgG.After incubation with the primary antibody,sections were washed with three changes of PBS and treated with fluorescein isothiocyanate(FITC)conjugated donkey anti-mouse secondary antibody diluted at 1:50 in PBS for 30 minutes at room temperature in a dark chamber.Thereafter the sections were extensively washed,mounted with aqueous UltraCruz Mounting Medium and then were examined with a fluorescence microscope Olympus BX 61 and images were taken by digital DP 71;Olympus CCD Image system attached to the fluorescence microscope. 9.Intracellular flow cytometry Intracellular cytokine staining was performed to assess the production of IL-17 by splenic lymphocytes.Cells were previously stimulated with 50 ng/ml PMA and 750 ng/ml Ionomycin in the presence of Brefeldin A 10μg/ml,for 4.5 h at 37℃in a humidified incubator with 5%CO2.To block Fc receptors,cells were preincubated with 1μg BD Fc Block reagent,for 15 min at 4℃.Cells were harvested and directly stained with surface markers anti-CD4-FITC(RM4-5)and anti-CD8-PE-Cy5 for 30 min at 4℃, followed by two washes in Staining Buffer.Cells were pellet by centrifugation at 2,000 rpm and then resuspended.To proceed with intracellular staining,cells were firstly fixed and permiabilized with BD Cytofix/Cytoperm solution for 20 min at 4℃. Thereafter,cells were washed twice with BD Perm/Wash buffer and then were stained intracellularly with anti-IL-17-PE(TC11-18H10.1)for 30 min at 4℃.Cells were pellet, resuspended in Staining Buffer and analyzed by flow cytometry. Results 1.rIL-25 treated mice delayed developed of clinical symptoms and reduced severity of colitis In clinical assessment,DAI was found to be lower in the DSS+rIL-25 treated group than in the DSS treated group(p<0.05).At autopsy,in macroscopic inspection, the gross colons appearance in the DSS treated mice were found to exhibit typical signs of severe acute inflammation against a mild inflammation exhibited in the DSS+ rIL-25 treated group.Length of colons in the DSS treated group was significantly shortened by 32%while that of the DSS+rIL-25 treated group was shortened by 17% (p<0.05).In Histological analysis the histological scores in the DSS+rIL-25 treated group was significantly lower compared to that of the DSS treated group(p<0.05). The DSS treated group revealed grade 4 lesions in contrast to the DSS+rIL-25 treated group revealed grade 2 lesions. 2.rIL-25 reduces mice mortality during the development of acute DSS-induced colitis Acute colitis was successively induced all mice by administration of drinking water supplemented with 2.5%DSS for seven days.There was a markedly variation in survival of mice between all groups.Mice treated with 0.4μg rIL-25 shows a significant improvement.The survival of mice treated with 0.2μg rIL-25 was shortened. Our survival study indicates that different dose reproduce distinct effect. 3.Expression of IL-25 decreased in DSS-induced colitis Western-blot and immuno-fluoroscent analysis reveal the expression of IL-25 in the colonic tissues at protein level.IL-25 expression was shown to decrease with increase in severity of colitis.Colon surface epithelium cells were found to be cellular source for IL-25 production.Using RT-PCR technique,we detected the expression of IL-25 at mRNA level.The expression of IL-25 was detected in tissue homogenates by ELISA but not at significant level. 4.IL-25 show anti-inflammatory activities on acute DSS-induced colitis There level of colonic IFN-γ(p<0.01)was significantly lower in all mice treated with rIL-25 in comparison to the DSS treated mice.Contrarily,colonic elevation of IL-10(p<0.01),TGF-β1(p<0.01),and IL-23(p<0.01)was markedly in the DSS +rIL-25 treated group,but there was no significant difference found in the production of IL-17 between DSS+rIL-25 treated group and DSS treated group.The level of IL-4 was detectable in all experimental groups but at very lower level.Thus,IL-25 reduced acute colitis clinical symptoms and severity by inhibiting or suppressing expression of IFN-γwith subsequent induction of IL-10,TGF-β1 and IL-23 respectively. 5.Lower production of IL-17 by CD4+/CD8+T cells in the development of acute DSS-induced colitis We further performed intracellular cytokine staining to confirm the production of IL-17 by CD4+/CD8+T cells during development of acute colitis.As judged through cytometric fluorescent intensity of intracellular staining,we found lower expression of IL-17 by CD4+/CD8+T cells in both DSS+rIL-25 treated mice and DSS treated mice. Discussion The aim of this study was to evaluate the effect of IL-25 on inflammatory bowel diseases.Crohn's disease and ulcerative colitis are the major forms of inflammatory bowel diseases that despite extensive studies etiology behind these diseases remain uncertain.In the present study,firstly we investigated the expression of IL-25 in serum, spleen supernatant,and colonic tissue homogenates as well in the colonic tissue culture supernatant.Our findings reveal expression of IL-25 but at low level. We also performed survival study important to prove and confirm the effect of IL-25 on the development and progress of colon inflammation.Inhibitory effect of IL-25 was proven by low mortality rate observed in the mice treated with IL-25 with improved prolonged survival.That is to demonstrate an improved resistance in DSS toxicity in the colonic mucosal.Interestingly,treatment of IL-25 for three day instead of five was enough to prolong survival time and improve mice health recovery.These findings prove the effective role of IL-25 in the prevention of development of inflammation in colon. The detection of the presence of IL-25 contents on the colon reveals decrease in IL-25 expression in severe colitis.This suggestion was supported with findings in western blot analysis where protein level expression of IL-25 was found high intensity of protein bands on colonic tissue from normal mice but was shown to decrease in severe colitis.Thus this findings show dectrase in IL-25 expression in severe colitis as colonic epithelium cell assumed to be among the colonic cellular source for IL-25 In order to evaluate the effect of IL-25 on inflammatory bowel disease,using DSS we established acute colitis model with subsequent treatment of mice with rIL-25 at different concentration so that to be able to determine differential dose effect of IL-25 in the development and progress of acute colitis.Our study revealed inhibitory effect of IL-25 as evidence in the DSS+rIL-25 treated group whereby the mice exhibited delayed development of clinical symptoms including weight loss,diarrhea and rectal bleeding,together with exhibition of less severe colon inflammation of a mild form with low epithelium damage and infiltrate lymphocytes.However,these findings were shown to vary with dosage,suggesting dose dependence inhibition. Cytokine profile in the mice treated with rIL-25 demonstrated that IL-25 reduces the severity of acute colon inflammation by either direct inhibition or suppression of IFN-γwith subsequent induction of IL-10,TGF-Beta and IL-23.Even the lowest dose of IL-25 was sufficient to down-regulate the level of Th type 1 cytokine IFN-γ.IL-25. was found to have no association with IL-17 at the acute stage but the role of IL-4 still remains unknown.Therefore,delay in development of clinical symptoms with less severe colitis observed in the IL-25 treated mice were most likely to be result of a complex cytokine cascade that initiated or associated with IL-25.Despite presence of IL-I7 contents in the mice treated with IL-25,in the present acute colitis investigation we found that neither CD4+/CDS+T cells norγδT cells was shown to be responsible for the production of IL-17 at acute stage if colon inflammation. Conclusions 1.DSS-induced ulcerative colitis model is reliable,simple and reproducible model with cytokine profile resemble to human IBD 2.IL-25 can successful slow down the development of colitis-induced clinical symptoms and reduce colonic tissue injury and severity of acute colitis in dose dependent manner. 3.IL-25 can improve mice survival with full restoration of body weight within short space of time. 4.IL-25 expressed is decrease with increase in colitis. 5.IL-25 induces IL-10,TGF-β1 and IL-23 in the regulation of acute colitis 6.IL-25 show to play crucial role in the regulation of colitis by inhibiting or suppressing Th type 1 cytokine IFN-γ. 7.IL-25 possesses anti-inflammatory effect contrary to its fellow family members.


知网文化
【相似文献】
中国期刊全文数据库 前15条
1 CHEN Ya-yun;CHEN Mei-hua;HE Liang-mei;ZHENG Rong;LIU Yang-bin;LIU Zhi-ping;;Nod-like receptors in the development of intestinal inflammation and cancer[J];赣南医学院学报;2015年04期
2 ;Role of interleukin 18 in acute lung inflammation induced by gut ischemia repeifusion[J];World Journal of Gastroenterology;2005年29期
3 ;Changes of inflammation-associated cytokine expressions during early phase of experimental endotoxic shock in macaques[J];World Journal of Gastroenterology;2004年20期
4 夏洛蒂·利波夫;张源中;;溃疡性结肠炎的症状与治疗[J];科技信息;2010年28期
5 穆丽亚;余在先;;中药口服治疗轻中度溃疡性结肠炎的研究进展[J];世界最新医学信息文摘;2018年98期
6 朱艳;;美沙拉嗪缓释颗粒对溃疡性结肠炎相关性息肉的临床效果研究[J];结直肠肛门外科;2018年S2期
7 解占峰;;美沙拉嗪缓释颗粒治疗溃疡性结肠炎30例疗效观察[J];中国肛肠病杂志;2018年07期
8 董宁宁;周艳华;何振;焦月;;急性重度溃疡性结肠炎的治疗进展[J];临床和实验医学杂志;2017年24期
9 高中丽;李婷;邵香;;改良式中药保留灌肠治疗溃疡性结肠炎疗效观察及护理[J];山西医药杂志;2018年03期
10 许华;郑城英;刘玉娥;;溃疡性结肠炎患者的临床护理体会[J];按摩与康复医学;2017年07期
11 梁圣帝;;溃疡性结肠炎中药临床治疗体会[J];世界最新医学信息文摘;2018年30期
12 柯嘉;吴小剑;;治疗溃疡性结肠炎内外科转换时机的困惑和解析[J];中国实用内科杂志;2018年03期
13 贺春林;薛玲;;溃疡性结肠炎心理分析和护理对策研究[J];结直肠肛门外科;2018年S1期
14 陈东;;美沙拉嗪联合谷氨酰胺治疗溃疡性结肠炎疗效观察[J];世界最新医学信息文摘;2016年76期
15 霍锃宏;;益生菌联合康复新液治疗活动期轻中度溃疡性结肠炎的可行性观察[J];中国继续医学教育;2017年03期
中国重要会议论文全文数据库 前10条
1 Huatuo Zhu;Xinyong Wan;Wenguo Chen;Chaohui Yu;Min Yue;Yining Dai;Lihua Chen;;BAHD1:a gatekeeper to protect us from inflammation-associated colon disease?[A];2014年浙江省内科学学术年会青年医师论坛暨内科常见病规范化诊疗国家级学习班论文汇编[C];2014年
2 孙聪;方晨晔;;溃疡性结肠炎30例住院病例的回顾分析[A];第三十届全国中西医结合消化系统疾病学术会议论文集[C];2018年
3 陈辉;张小仙;冯新春;;隔药灸治疗溃疡性结肠炎的护理体会[A];中华中医药学会脾胃病分会第二十五届全国脾胃病学术交流会论文汇编[C];2013年
4 方煊;;中西医结合治疗溃疡性结肠炎180例[A];中国肛肠病诊疗集萃[C];2014年
5 许小鑫;俞惠翻;林鹏锋;黄文辉;;布地奈德治疗轻-中度溃疡性结肠炎的循证评价[A];2014年中国药学大会暨第十四届中国药师周论文集[C];2014年
6 窦丹波;黄艳芳;李刚;张正利;岑戎;;溃结通治疗轻中度溃疡性结肠炎随机对照临床研究[A];第二十一届全国中西医结合消化系统疾病学术会议暨国家级中西医结合消化系统疾病新进展学习班论文汇编[C];2009年
7 聂娜;;溃疡性结肠炎中药保留灌肠的护理[A];中华中医药学会第十二次大肠肛门病学术会议论文汇编[C];2006年
8 任南新;;肠愈Ⅰ号汤治疗溃疡性结肠炎临床应用[A];中华中医药学会脾胃病分会第十九次全国脾胃病学术交流会论文汇编[C];2007年
9 张晓峰;;中药治疗溃疡性结肠炎的思路与方法[A];中华中医药学会脾胃病分会第十九次全国脾胃病学术交流会论文汇编[C];2007年
10 李敏;梁超;;血竭治疗溃疡性结肠炎的思路与方法[A];中华中医药学会脾胃病分会第十九次全国脾胃病学术交流会论文汇编[C];2007年
中国博士学位论文全文数据库 前10条
1 Salum Seif Salum Mchenga;rIL-25在急性溃疡性结肠炎中的抗炎症效应[D];中国医科大学;2009年
2 卫珮如;中重度溃疡性结肠炎的药物治疗及疗效相关因素分析[D];南方医科大学;2018年
3 牛俊坤;HSF2在溃疡性结肠炎粘膜愈合中的作用及机制研究[D];昆明医科大学;2018年
4 周江韬;鸦胆子苦醇自微乳对溃疡性结肠炎的治疗作用研究[D];广州中医药大学;2018年
5 王兰菊;GDF11对小鼠溃疡性结肠炎的保护作用及机制研究[D];郑州大学;2018年
6 刘超;毛蕊异黄酮对溃疡性结肠炎小鼠的治疗作用及其机制研究[D];郑州大学;2017年
7 吴限;结肠灵治疗溃疡性结肠炎的实验与临床研究[D];黑龙江中医药大学;2004年
8 杜廷龙;“黄芪香参颗粒”治疗溃疡性结肠炎的研究[D];南京中医药大学;2004年
9 庞艳华;STAT4和STAT6以及Th1/Th2类细胞因子在溃疡性结肠炎中的表达[D];中国医科大学;2005年
10 石忠峰;溃疡性结肠炎靶向治疗新药白术黄芪胶囊药学与药理学研究[D];广州中医药大学;2005年
中国硕士学位论文全文数据库 前10条
1 孙晓艳;基于五运六气溃疡性结肠炎临床研究[D];北京中医药大学;2019年
2 杨雪;清热除湿化瘀解毒中药灌肠方治疗溃疡性结肠炎近期疗效的观察[D];北京中医药大学;2016年
3 赵辉;自拟愈疡汤1号治疗溃疡性结肠炎的临床研究[D];黑龙江中医药大学;2018年
4 韦德锋;溃疡性结肠炎中医证候与肠镜象相关性研究[D];广西中医药大学;2018年
5 韦日娜;安肠汤联合美沙拉嗪治疗脾肾阳虚型溃疡性结肠炎的临床观察[D];广西中医药大学;2018年
6 李晶;溃结爽口服方不同组分在溃疡性结肠炎治疗中的效应分析[D];河北北方学院;2018年
7 权娜娜;黄芩汤加减联合康复新液保留灌肠治疗湿热型溃疡性结肠炎临床疗效[D];成都中医药大学;2018年
8 王会沙;化浊解毒愈疡煎对溃疡性结肠炎大鼠GSH、GSH-Px、IFN-γ表达的影响[D];河北医科大学;2018年
9 孙乾;GABA能信号系统破坏肠粘膜屏障及其在溃疡性结肠炎中的作用及机制[D];山东大学;2018年
10 马旭园;溃疡性结肠炎患者肠道菌群变化及其与IL-23/IL-17轴的关系[D];河南大学;2018年
中国重要报纸全文数据库 前10条
1 本报记者 杨六香;溃疡性结肠炎:须重视长期维持治疗[N];中国医药报;2017年
2 上海中医药大学附属岳阳中西医结合医院肛肠科 杨迪迪 夏宇虹 吴闯;溃疡性结肠炎——长期慢性腹泻腹痛的隐藏“祸首”[N];上海中医药报;2017年
3 本报见习记者 黄杨子;治疗溃疡性结肠炎,中医有何方[N];解放日报;2015年
4 北京中医医院消化中心 张声生 赵鲁卿;溃疡性结肠炎 哪些药哪些方管用[N];健康报;2016年
5 本报记者 慕欣 王雪敏 魏平;溃疡性结肠炎:要诊断 先排查[N];医药经济报;2011年
6 袁虎;患溃疡性结肠炎要重调养[N];医药养生保健报;2009年
7 伏新顺 青海省中医院;溃疡性结肠炎辨治六型[N];中国中医药报;2009年
8 张超群 黄智斌;山西研制出治溃疡性结肠炎新药[N];中国医药报;2002年
9 万同己;溃疡性结肠炎与血小板功能状态[N];中国医药报;2003年
10 剑 钟;隔药灸治疗溃疡性结肠炎疗效显著[N];中国中医药报;2002年
 快捷付款方式  订购知网充值卡  订购热线  帮助中心
  • 400-819-9993
  • 010-62982499
  • 010-62783978